seeding, the medium was removed and the cells were then incubated in serum free-DMEM containing bovine serum albumin (0.25% w/v) and supplements (L-glutamine, sodium pyruvate and nonessential amino acids) for a further 24 h before the addition of human plasminogen (0.5-50 g/mL, Roche) or human plasmin (0.5-50 mU/mL, Roche). After an additional 24 h, culture supernatants were collected for assay of IL-6. In selected experiments, pharmacological inhibitors were added to cell culture medium at a final concentration of 10 M, 30 min before the addition of plasmin(ogen).
The final concentration of DMSO, the diluent for these inhibitors, was 0.1 % v/v, and all cells were exposed to the same concentration of DMSO. The inhibitors used were: UK122 for uPA; LY294002
for PI3K/Akt; PD98059 for ERK1/2; and SB203580 for p38 MAPK. In selected experiments, anti-PAR-1 (ATAP2, Santa Cruz Biotechnology, USA), anti-IL-6 (BD Biosciences, CA, USA) or control IgGs (Santa Cruz Biotechnology, USA) were used at 2 g/mL.
Cell enumeration
After 48 
RNA extraction and real-time polymerase chain reaction (PCR)
RNA was purified from cells maintained in either 24 or 96 well culture plates using Trizol (Invitrogen), according to the manufacturer's instructions. RNA was extracted from lung tissue using
Qiagen mini prep columns (Qiagen), according to the manufacturer's instructions. Before RNA extraction, frozen tissue was crushed using a mortar and pestle in liquid N2 to prevent thawing.
Reverse transcription of total RNA and the subsequent real-time polymerase chain reaction using an ABI Prism 7900HT sequence detection system (Applied Biosystems) with the relevant forward and reverse primers were conducted as previously described (1). The following primers were used: , where CT is equal to the CT value of the target gene minus the CT value of 18S rRNA.
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Figure legends 
